Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to index

Cancer Chemotherapy Regimen for Ovarian Cancer


 H-CMF                                                ovarian(116)
 _________________________________________________________________
  hexamethylmelami 150 mg/day orally from day 1 to day 14.
  cytoxan......... 150 mg/day orally from day 1 to day 14.
  methotrexate.... 40 mg/sqm IV on day 1 and day 8.
  fluorouracil.... 600 mg/sqm IV on day 1 and day 8.
  FREQUENCY....... Repeat cycle every 28 days.

  reference...
    Young RC.  Chabner BA.  Hubbard SP.  Fisher RI.  Bender RA. 
    Anderson T.  Simon RM.  Canellos GP.  DeVita VT Jr. Advanced 
    ovarian adenocarcinoma. A prospective clinical trial of 
    melphalan (L-PAM) versus combination chemotherapy. New England 
    Journal of Medicine.  299(23):1261-6, 1978 Dec 7. 
  abstract...
    Eighty patients with advanced ovarian adenocarcinoma were 
    treated in a prospective, randomized trial comparing a 
    four-drug combination--hexamethylmelamine, cyclophosphamide, 
    methotrexate and 5-fluorouracil--with the oral alkylating 
    agent, melphalan. Treatment with the four-drug combination was 
    associated with a significantly increased overall response 
    rate (75 vs. 54 per cent) (P less than 0.05), more complete 
    remissions (33 vs. 16 per cent) and longer median survival (29 
    vs. 17 months) (P less than 0.02) but more severe toxicity 
    than occurred with melphalan. Patients with minimal residual 
    disease had a significantly higher overall response rate than 
    patients with extensive residual disease (84 vs. 53 per cent) 
    (P less than 0.05). Patients with advanced disease who 
    achieved a complete remission documented by peritoneoscopy or 
    laparotomy (or both) have a median survival that will exceed 
    three years. The four-drug regimen is more effective than 
    melphalan in the management of advanced ovarian 
    adenocarcinoma. 
 

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 

 advertisement.gif (61x7 -- 0 bytes)

 

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.